You are here

Article info

Article menu

Download PDFPDF

Correspondence
Dupilumab as a potential steroid-sparing treatment for IgG4-related disease
Free

Authors

  • Emanuel Della-Torre Università Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy Unit of Immunology, Rheumatology, Allergy, and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy PubMed articlesGoogle scholar articles
  • Marco Lanzillotta Università Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy Unit of Immunology, Rheumatology, Allergy, and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy PubMed articlesGoogle scholar articles
  • Mona-Rita Yacoub Università Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy Unit of Immunology, Rheumatology, Allergy, and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Emanuel Della-Torre, Università Vita-Salute San Raffaele, San Raffaele Scientific Institute, 20132 Milano, Italy; dellatorre.emanuel{at}hsr.it
View Full Text

Citation

Della-Torre E, Lanzillotta M, Yacoub M
Dupilumab as a potential steroid-sparing treatment for IgG4-related disease
Annals of the Rheumatic Diseases 2022;81:e24.

Publication history

  • Received January 5, 2020
  • Accepted January 7, 2020
  • First published January 14, 2020.
Online issue publication 
April 17, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.